Hortense Slevogt appointed to expert panel against antibiotic resistance

The increasing development of antimicrobial resistance (AMR) is an acute global threat that must be addressed from scientific, clinical, and public health policy perspectives. The ART Commission evaluates diagnostic and therapeutic approaches to infectious diseases, with particular attention to the development of antimicrobial resistance, and derives practical, guideline-based recommendations for clinical practice and public health.

Her involvement in the commission is directly linked to Slevogt’s scientific and clinical work. At the HZI, she and her research group “Dynamics of Respiratory Infections” investigate the role of the microbiome in inflammatory and infectious processes in the respiratory tract. At the same time, she serves as a lead senior physician for Clinical Infectiology at the Clinic for Pneumology and Infectiology at the MHH.

“Antimicrobials are essential for the treatment of pulmonary infections, which continue to represent a major disease burden worldwide. At the same time, rising antimicrobial resistance poses an acute global threat,” says Slevogt. “The work in the RKI’s ART Commission makes it possible to translate these challenges into concrete, guideline-based recommendations for diagnosis and treatment based on scientific evidence, thereby contributing to the implementation of national and international AMR strategies.”

The commission plays an important role in implementing the German Antibiotic Resistance Strategy (DART). It works closely with professional societies, the Association of Scientific Medical Societies (AWMF), and other healthcare institutions. Its members are reappointed every four years.